A Prospective Study of the Clinical and Demographic Profile of Type 2 Diabetes Mellitus Patients Receiving Antidiabetic Drug Combinations

Title:A Prospective Study of the Clinical and Demographic Profile of Type 2 Diabetes Mellitus Patients Receiving Antidiabetic Drug Combinations

Volume: 16 Issue: 5

Author(s): Akash Gadgade, Ashok S. Kudgi*, Ashwin Kamath, Priyanka Kamath, Prabha Adhikari, Nishith S. Revappala, Sanjay Hadigal, Srikant Natarajan, Nandita Shenoy and Mukta N. Chowta

Affiliation:

• Department of Pharmacology, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, Karnataka 575001,India

Keywords: Diabetes mellitus, pharmacotherapy, fixed-dose combination, metformin, sulfonylurea, glycated hemoglobin.

Abstract:

Background: The specific treatment recommendations for type 2 diabetes mellitus (T2DM) differ based on a particular guideline. The goal of pharmacotherapy is to achieve the target HbA1c and fasting and postprandial blood glucose levels to avoid disease complications.

Objective: To evaluate the profile of T2DM patients on different antidiabetic treatment regimens and the factors leading to dose escalation in these patients.

Methods: A prospective descriptive study was conducted at Kasturba Medical College Hospital, Mangalore, a tertiary care teaching hospital, over a period of one year. The study population comprised of patients with T2DM for ≥5 years. The demographic and clinical data were collected during the baseline and follow-up visits.

Results: Of the 119 patients studied, 59.7% were males; 32.8% were ≥65 years of age. A significant decrease in the fasting blood glucose (FBG) on follow-up was seen (p = 0.028) in patients on sulfonylurea and metformin combination. A significant decrease in the glycated haemoglobin (HbA1c) was seen in patients on sulfonylurea with metformin and pioglitazone (p = 0.011); sulfonylurea with metformin, pioglitazone, and sitagliptin (p = 0.026); and metformin with insulin (p = 0.001). Patients who received dose escalation had a longer duration of the disease (p = 0.042), higher FBG (p = 0.039) and HbA1c (p = 0.05).

Conclusion: A combination of metformin with sulfonylurea was the preferred first-line treatment; insulin was added when HbA1c was >9. Patients who received dose escalation had a longer duration of the disease and higher FBG and HbA1c.

Cite this article as:

Gadgade Akash, Kudgi S. Ashok*, Kamath Ashwin, Kamath Priyanka, Adhikari Prabha, Revappala S. Nishith, Hadigal Sanjay, Natarajan Srikant, Shenoy Nandita and Chowta N. Mukta, A Prospective Study of the Clinical and Demographic Profile of Type 2 Diabetes Mellitus Patients Receiving Antidiabetic Drug Combinations, Current Diabetes Reviews 2020; 16 (5) . https://dx.doi.org/10.2174/1573399815666190619125857